International healthcare consultancy in health policy advisory, health technology assessment (HTA), investment planning. Graduated medicine, has MBA from AUBG, masters in public health, holds a PhD in HTA, completed executive education in Value measurement for healthcare (VMHC) at Harvard Business School. Teaches HTA, pharmacoeconomics, VMHC, co-author of >10 books on relevant topics and >90 scientific papers. For the last 6 years he’s managing HTA Ltd., with >600 analyses, >130 of them for orphan drugs, rare diseases; 19/20 top Pharma, 3/5 top medical devices companies. Since 2017 Dr. Djambazov has been active with health policy advisory and large health investment projects in Africa, Central and South East Asia.
Chemotherapy Clinic, USHAT in oncology - Sofia